Oculis (NASDAQ:OCS) Posts Earnings Results, Misses Expectations By $0.28 EPS

Oculis (NASDAQ:OCS) announced its quarterly earnings results on Tuesday. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28), Zacks reports. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

Oculis Stock Performance

Oculis stock traded up $0.10 during mid-day trading on Tuesday, hitting $18.40. 59,598 shares of the company’s stock traded hands, compared to its average volume of 87,312. Oculis has a one year low of $10.55 and a one year high of $23.08. The company has a market cap of $745.27 million, a PE ratio of -9.53 and a beta of 0.01. The firm has a 50 day moving average price of $20.79 and a 200 day moving average price of $16.82. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

OCS has been the topic of a number of recent research reports. Chardan Capital reiterated a “buy” rating and issued a $28.00 target price on shares of Oculis in a research note on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Oculis in a research report on Monday, January 6th.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.